Literature DB >> 12694311

Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients.

Marta Kalousová1, Tomás Zima, Vladimír Tesar, Sylvie Sulková, Lenka Fialová.   

Abstract

Uremia and dialysis treatment are associated with uncorrected oxidative and carbonyl stress and microinflammation. Elevation of both oxidative/carbonyl stress end products (advanced oxidation protein products (AOPP), advanced glycation end products (AGEs), and advanced lipoperoxidation end products (ALEs), autoantibodies against modified biological structures, and acute-phase reactants (e.g., C-reactive protein [CRP], fibrinogen) seems to take part in the development of various complications, among them accelerated atherosclerosis. These pathogenic mechanisms are supposed to act synergically; nevertheless, oxidative stress shows a closer relationship to inflammation and acute-phase reaction than advanced glycation. Its end product, AOPP, could, thus, represent a biochemical marker of specific importance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694311     DOI: 10.1046/j.1523-1755.63.s84.19.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  3 in total

1.  Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels.

Authors:  Tinghuai Wu; Masashi Fujihara; Jane Tian; Miroslava Jovanovic; Celene Grayson; Marisol Cano; Peter Gehlbach; Philippe Margaron; James T Handa
Journal:  J Neurochem       Date:  2010-07-27       Impact factor: 5.372

2.  Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.

Authors:  Oskar Zakiyanov; Vitezslav Kriha; Jan Vachek; Tomas Zima; Vladimir Tesar; Marta Kalousova
Journal:  BMC Nephrol       Date:  2013-11-04       Impact factor: 2.388

3.  Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.

Authors:  Masato Ohsawa; Kouichi Tamura; Hiromichi Wakui; Tomohiko Kanaoka; Kengo Azushima; Kazushi Uneda; Sona Haku; Ryu Kobayashi; Kohji Ohki; Kotaro Haruhara; Sho Kinguchi; Yoshiyuki Toya; Satoshi Umemura
Journal:  Lipids Health Dis       Date:  2015-12-09       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.